Literature DB >> 21036737

Differential suppression of proliferation in MCF-7 and MDA-MB-231 breast cancer cells exposed to alpha-, gamma- and delta-tocotrienols is accompanied by altered expression of oxidative stress modulatory enzymes.

Tze-Chen Hsieh1, Selvakumar Elangovan, Joseph M Wu.   

Abstract

Tocotrienols belong to the vitamin E family of chemicals known to have potent anti-proliferative and apoptotic activities against a variety of cancer cells with little to no comparable influence on the normal cells. Whether tocotrienols control the expression of phase II antioxidant enzymes in the context of their anti-carcinogenic mechanisms has not been investigated. The present studies were performed to test whether the differential growth inhibition resulting from exposure to α-, γ- and δ-tocotrienols in estrogen receptor-positive human MCF-7 and estrogen receptor-negative MDA-MB-231 breast cancer cells might be accompanied by changes in phase II antioxidant enzymes. Cell proliferation and clonogenicity in both cell lines were significantly inhibited by γ- and δ-tocotrienols with little affect when cells were similarly exposed to α-tocotrienol, at doses up to 10 μM. The expression and activity of several antioxidant enzymes in 10 μM tocotrienol-treated cells were determined by Western blot and biochemical assays. In MDA-MB-231 cells, δ- was more active than α- or γ-tocotrienols in up-regulating glutathione peroxidase; however, the three tocotrienols had comparable activity in inducing thioredoxin. In MCF-7 cells, expression of quinone reductase 2 and thioredoxin was increased by γ- and δ-tocotrienols, whereas quinone reductase 1 was unaffected by exposure to the tocotrienols. The tocotrienols also did not affect the expression and activity of superoxide dismutase in both MCF-7 and MDA-MB-231 cells, but increased catalase activity concomitant with slight reduction in the catalase expression. In MDA-MB-231 cells, treatment by tocotrienols led to several fold increase of NRF2 expression marked by corresponding decrease in KEAP1 levels. By contrast, no significant change in NRF2 and KEAP1 levels was observed in MCF-7 cells. These studies demonstrate that different tocotrienols show distinct and selective activity in regulating the NRF2-KEAP1, in coordination with the induced expression of cytoprotective oxidative stress modulatory genes and regulation of proliferation in breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21036737

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  16 in total

1.  MiR-28 regulates Nrf2 expression through a Keap1-independent mechanism.

Authors:  Muhua Yang; Yuan Yao; Gabriel Eades; Yongshu Zhang; Qun Zhou
Journal:  Breast Cancer Res Treat       Date:  2011-06-03       Impact factor: 4.872

2.  Tocotrienols fight cancer by targeting multiple cell signaling pathways.

Authors:  Ramaswamy Kannappan; Subash C Gupta; Ji Hye Kim; Bharat B Aggarwal
Journal:  Genes Nutr       Date:  2011-04-09       Impact factor: 5.523

3.  miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells.

Authors:  Gabriel Eades; Muhua Yang; Yuan Yao; Yongshu Zhang; Qun Zhou
Journal:  J Biol Chem       Date:  2011-09-16       Impact factor: 5.157

4.  Why tocotrienols work better: insights into the in vitro anti-cancer mechanism of vitamin E.

Authors:  Valentina Viola; Francesca Pilolli; Marta Piroddi; Elisa Pierpaoli; Fiorenza Orlando; Mauro Provinciali; Michele Betti; Francesco Mazzini; Francesco Galli
Journal:  Genes Nutr       Date:  2011-04-20       Impact factor: 5.523

5.  Genistein induces apoptosis and autophagy in human breast MCF-7 cells by modulating the expression of proapoptotic factors and oxidative stress enzymes.

Authors:  R F Prietsch; L G Monte; F A da Silva; F T Beira; F A B Del Pino; V F Campos; T Collares; L S Pinto; R M Spanevello; G D Gamaro; E Braganhol
Journal:  Mol Cell Biochem       Date:  2014-02-27       Impact factor: 3.396

6.  Anticancer therapeutic potential of Mn porphyrin/ascorbate system.

Authors:  Artak Tovmasyan; Romulo S Sampaio; Mary-Keara Boss; Jacqueline C Bueno-Janice; Bader H Bader; Milini Thomas; Julio S Reboucas; Michael Orr; Joshua D Chandler; Young-Mi Go; Dean P Jones; Talaignair N Venkatraman; Sinisa Haberle; Natalia Kyui; Christopher D Lascola; Mark W Dewhirst; Ivan Spasojevic; Ludmil Benov; Ines Batinic-Haberle
Journal:  Free Radic Biol Med       Date:  2015-10-20       Impact factor: 7.376

7.  Gamma-tocotrienol treatment increased peroxiredoxin-4 expression in HepG2 liver cancer cell line.

Authors:  Farahani Abdul Rahman Sazli; Zakiah Jubri; Mariati Abdul Rahman; Saiful Anuar Karsani; Abdul Gapor Md Top; Wan Zurinah Wan Ngah
Journal:  BMC Complement Altern Med       Date:  2015-03-13       Impact factor: 3.659

8.  Dietary Tocotrienol/γ-Cyclodextrin Complex Increases Mitochondrial Membrane Potential and ATP Concentrations in the Brains of Aged Mice.

Authors:  Anke Schloesser; Tuba Esatbeyoglu; Stefanie Piegholdt; Janina Dose; Naoko Ikuta; Hinako Okamoto; Yoshiyuki Ishida; Keiji Terao; Seiichi Matsugo; Gerald Rimbach
Journal:  Oxid Med Cell Longev       Date:  2015-08-02       Impact factor: 6.543

9.  Evaluation of cytotoxic and anti-inflammatory activities of extracts and lectins from Moringa oleifera seeds.

Authors:  Larissa Cardoso Corrêa Araújo; Jaciana Santos Aguiar; Thiago Henrique Napoleão; Fernanda Virgínia Barreto Mota; André Luiz Souza Barros; Maiara Celine Moura; Marília Cavalcanti Coriolano; Luana Cassandra Breitenbach Barroso Coelho; Teresinha Gonçalves Silva; Patrícia Maria Guedes Paiva
Journal:  PLoS One       Date:  2013-12-09       Impact factor: 3.240

Review 10.  Synergistic Anticancer Effect of Tocotrienol Combined with Chemotherapeutic Agents or Dietary Components: A Review.

Authors:  Takahiro Eitsuka; Naoto Tatewaki; Hiroshi Nishida; Kiyotaka Nakagawa; Teruo Miyazawa
Journal:  Int J Mol Sci       Date:  2016-09-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.